Table.3 Subgroup analysis of calprotectin for PJI diagnosis
Subgroup analyses | No. of studies | Sensitivity (95% CI) | Specificity (95% CI) | PLR (95% CI) | NLR (95% CI) | AUC (95% CI) | Diagnostic score (95% CI) | DOR (95% CI) | I2(Sen) (95% CI) | P-value (Sen) | I2(Spe) (95% CI) | P-value (Spe) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Overall studies | 7 | 0.94 (0.87–0.98) | 0.93 (0.87–0.96) | 13.7 (6.9–27.1) | 0.06 (0.02–0.15) | 0.98 (0.96–0.99) | 5.4 (3.96–6.85) | 222 (53–941) | 71.11 | 0.00 | 76.90 | 0.00 |
Prospective | 6 | 0.96 (0.91–0.98) | 0.95 (0.91–0.97) | 17.6 (10.5–29.4) | 0.05 (0.02–0.10) | 0.98 (0.96–0.99) | 5.94 (4.95–6.93) | 378 (141–1018) | 31.00 | 0.20 | 87.49 | 0.00 |
50 mg/L | 4 | 0.96 (0.87–0.99) | 0.94 (0.89–0.97) | 15.4 (8.3–28.5) | 0.04 (0.01–0.15) | 0.97 (0.95–0.98) | 5.85 (4.29–7.40) | 346 (73–1638) | 54.15 | 0.09 | 0.00 | 0.64 |
Western countries | 6 | 0.94 (0.85–0.98) | 0.92 (0.85–0.96) | 11.9 (5.9–24.01) | 0.07 (0.02–0.18) | 0.97 (0.96–0.98) | 5.21 (3.65–6.77) | 183 (39–871) | 73.90 | 0.00 | 75.90 | 0.00 |
MSIS | 4 | 0.94 (0.86–0.98) | 0.94 (0.89–0.97) | 16.3 (8.7–30.8) | 0.06 (0.02–0.15) | 0.98 (0.96–0.99) | 5.60 (4.34–6.86) | 271 (77–958) | 23.46 | 0.27 | 0.00 | 0.45 |